Celldex shares slip 15% as safety concerns cloud skin drug trial win

As reported by Markets-Economic Times

(Rewrites throughout to add company comments, adds shares in paragraph 2, analyst comment in paragraph 5)- Celldex Therapeutics said on Tuesday its experimental

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Markets-Economic Times ↗

Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.

INDIAN Orient Cables, AceVector, German Green Steel announce IPO price bands Share Market Today
INDIAN NSE IPO: 20 investment bankers earn ₹186 crore in fees, commissions Share Market Today
INDIAN Hikal commences commercial production of personal care products Share Market Today
INDIAN Runwal Enterprises aims to boost balance sheet via ₹500 crore issue Share Market Today
INDIAN Nifty 50 deep-dive guide for investors: Bearish engulfing candlestick; check resistance, support levels | Wed 23 Sept mint - markets
INDIAN Why are foreign investors leaving Indian stocks? Bernstein flags ‘bygone’ large-cap businesses, low AI exposure mint - markets
INDIAN Why NSE IPO became India's 2nd-largest, not biggest: MD-CEO Ashishkumar Chauhan explains | Exclusive mint - markets
INDIAN Top breakout stocks to buy today: Swiggy, Welspun, Finolex, Vishal Mega Mart, Carborundum by Sumeet Bagadia | Targets mint - markets

Celldex shares slip 15% as safety concerns cloud skin drug trial win

More from Market Samachar